In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
John L. Berk, MD
Associate Professor of Medicine
Director, Clinical Trials for Familial Amyloidosis
Director, Localized Amyloid Clinic
Chobanian & Avedisian School of Medicine: Amyloidosis Center
Boston University
Boston, MA
Dr. Berk has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Intellia
Research: Alnylam, AstraZeneca, BridgeBio, Ionis
Royalties: Merck, UpToDate
Noel Dasgupta, MD, FACC
Associate Professor of Clinical Medicine and Pathology & Laboratory Medicine
Krannert Institute of Cardiology
Indiana University
Indianapolis, IN
Dr. Dasgupta has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alnylam, AstraZeneca, BridgeBio, Novo Nordisk
Research: Alexion, Alnylam, Eidos, Intellia, Ionis
Sami Khella, MD
Professor of Neurology
Penn Presbyterian Medical Center
Department of Neurology
University of Pennsylvania School of Medicine
Philadelphia, PA
Dr. Khella has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alnylam, Alexion, AstraZeneca, Ionis, Pfizer
Marcia Waddington-Cruz, MD, PhD
Neurologist
National Amyloidosis Referral Center
Federal University of Rio de Janeiro
Rio de Janeiro, Brazil
Dr. Waddington-Cruz has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alnylam, AstraZeneca, Ionis, Pfizer, PTC
Research: Alnylam, Ionis
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Howard Green has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
- Mario Trucillo, PhD, has nothing to disclose.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 23, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
